ADVM - Adverum Biotechnologies, Inc.
IEX Last Trade
4.71
-0.120 -2.548%
Share volume: 1
Last Updated: Thu 26 Dec 2024 03:29:06 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$4.83
-0.12
-2.48%
Fundamental analysis
8%
Profitability
8%
Dept financing
4%
Liquidity
50%
Performance
0%
Performance
5 Days
0 0%
1 Month
-22.93%
3 Months
-28.07%
6 Months
-31.40%
1 Year
500.00%
2 Year
731.58%
Key data
Stock price
$4.71
DAY RANGE
$4.83 - $4.83
52 WEEK RANGE
$0.78 - $29.70
52 WEEK CHANGE
-$37.05
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Laurent Fischer
Region: US
Website: adverum.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: adverum.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Adverum Biotechnologies, Inc. develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Recent news